Opportunity for Adult Bonding/Meaningful Neighborhood Roles and Life-Satisfaction among USA Middle School Students

This study investigated the relationship between adolescent life- satisfaction and bonding to adults/developing meaningful roles in the neighborhood within a pilot study of slightly modified version of the CDC Middle School Youth Risk Behavior Survey (MSYRBS) in a southern state in the USA. Overall, 43% of students reported that they were satisfied with their lives overall, and 34% reported that they experienced positive adult relationships and meaningful roles in their neighborhoods. After adjusting for socioeconomic status and family structure, differential associations were found between adolescent life satisfaction and bonding to adults/developing meaningful roles. Opportunities for adult bonding and meaningful roles in the neighborhood related to increased life satisfaction more strongly for Caucasian students than African-American students. Post-Hoc analyses suggest that the explanation for these differential relationships may involve socioeconomic status. *This research was conducted via the South Carolina Middle School Youth Risk Behaviour Survey funded by the CDC/Legacy Foundation, Atlanta, Georgia in cooperation with the South Carolina Department of Health & Environmental Control, Columbia, South Carolina.     

Structural Flaws in the Bridge From Basic Research on Marriage to Interventions for Couples

In an article that received widespread media attention, Gottman, Coan, Carrère, and Swanson (1998) reported on a longitudinal study of newlywed couples and recommended major changes in the practice of marital therapy and education. Most notably, they called for the abandonment of interventions that promote active listening, they concluded that anger was not detrimental to marital outcomes, and they advocated an interaction pattern wherein wives raise issues more gently and husbands more readily accept wives' influence. Because of several methodological and conceptual shortcomings, the recommendations of Gottman et al. appear to us to be premature at best. We raise methodological concerns about the nonrandom selection of research subjects, failure to control for factors that may have differentiated couples initially, procedural issues regarding observational and physiological data, and ambiguity about statistical tests employed. We raise conceptual concerns about how the labeling of patterns affects the conclusions drawn and also about the use of correlational data to make strong causal inferences. We conclude that the article by Gottman et al. risks influencing couples and practitioners alike in a manner that, in our view, exceeds the scope and methods of the underlying research.     

Does consensus bargaining control labor costs in Japan? Evidence from the “bubble economy” and its aftermath

Japan’s system of labor negotiations provides an opportunity to see whether consensus bargaining restrains labor costs. The recent volatility of the Japanese economy affords a unique chance to observe how consensus-based labor settlements adjusted to sudden, sharp changes in market conditions. It is also possible to evaluate the role of bonus payments in amending labor settlements. With observations for 1986–1995,1 use measures of productivity gains to calculate the capacity for increasing worker pay and then analyze whether pay increases exceeded that capacity. I report the extent to which changes in labor earnings were scheduled or resulted from adjustments in bonus pay. During the boom years of the late 1980s, employers inflated bonuses so that workers’ pay increased more than had been scheduled, but not enough to exceed the capacity for growth. But during the sluggish years of the early 1990s, pay agreements were excessive. Employers cut workers’ bonuses to keep earnings growth in check. Thus, bonus pay provided a “degree of freedom” allowing employers to adjust labor costs following sudden upswings and downturns in the economy. I am grateful to Professor Hideo Kawada and Mr. Kenichi Matsuki, both of Senshu University, for their assistance in gathering the earnings data for this study. Thanks are also due to Craig MacPhee, Roger Riefler, and Hendrik Van den Berg for thoughtful comments and suggestions. I am responsible for any remaining shortcomings.     

On Determining the Dimension of Real-Time Stock-Price Data

We estimate the dimension of high-frequency stock-price data using the correlation integral of Grassberger and Procaccia. The data, even after filtering, appear to be of low dimension. To control for dependence in higher moments, we use a new technique known as the method of delays in our reconstruction. Delaying the data leads dimension estimates similar to random processes. We conclude that the data are either of low dimension with high entropy or nonlinear but of high dimension.     

Bayesian adaptive two-stage design for determining person-time in Phase II clinical trials with Poisson data

Adaptive clinical trial designs can often improve drug-study efficiency by utilizing data obtained during the course of the trial. We present a novel Bayesian two-stage adaptive design for Phase II clinical trials with Poisson-distributed outcomes that allows for person-observation-time adjustments for early termination due to either futility or efficacy. Our design is motivated by the adaptive trial from [9 V. Sambucini, A Bayesian predictive two-stage design for Phase II clinical trials, Stat. Med. 27 (2008), pp. 1199–1224. doi: 10.1002/sim.3021[Crossref], [PubMed], [Web of Science ®] , [Google Scholar]], which uses binomial data. Although many frequentist and Bayesian two-stage adaptive designs for count data have been proposed in the literature, many designs do not allow for person-time adjustments after the first stage. This restriction limits flexibility in the study design. However, our proposed design allows for such flexibility by basing the second-stage person-time on the first-stage observed-count data. We demonstrate the implementation of our Bayesian predictive adaptive two-stage design using a hypothetical Phase II trial of Immune Globulin (Intravenous).